Archive | April, 2011

Rayno Diagnostics and Tools Market Update: GenProbe (GPRO),Illumina (ILMN),Quidel (QDEL)

Earnings season has begun with good results. Keep in mind the following trends: technology convergence, molecular diagnostics and M&A. The backdrop for the tools market is proposed government cuts in government scientific spending especially NIH. Leerink Swann data from the Dept. of Health and Human services projects NIH funding cutbacks in 2011 and 2012 of […]

Continue Reading 0

Rayno Life Science Portfolio Dx and Tools: GenProbe (GPRO) Soars On “For Sale”

Earnings season for diagnostics and tools companies begins today with GenProbe (GPRO $79.39) after the market close. But the stock is up 13% today on a Bloomberg scoop that the Company has hired Morgan Stanley as an investment banker to seek a buyer. The market cap is $3.8B with a 2011 forecasted Revenue of $582M […]

Continue Reading 0

Biotech Rocks On: Rayno Life Science Portfolio Up 2.2 % Led By Regeneron (REGN)

The biotech bulls are in charge this week. The sellers must have been watching the Bernanke Press Conference today or maybe buying gold as biotech stocks had one of their best days of the year. The bellwether ETF IBB was up 2.37% to $108.71 an all time high exceeding its high of $105 in June […]

Continue Reading 0

Biotech Sector Ignited By Biogen-Idec (BIIB) and Vertex (VRTX)

Vertex (VRTX $54.17) soared 12.75% today on expectations for FDA approval of it telaprevir HCV drug Thursday April 28. Today FDA staff in a preliminary review commented that the Vertex drug when combined with current therapies is more effective than those drugs alone. The FDA team confirmed telaprevir’s efficacy findings and secondary endpoint analysis  for […]

Continue Reading 0

Rayno Life Science Market ReCap-Quiet Day but More Red than Green

Caution is still on as we have had big moves YTD and speculative stocks are selling off. High flyers Amarin (AMRN $16.10) is down 4.85% on volume of  6.85M shares while Ariad (ARIA $8.14) was down 3.2% on volume of 1.5M shares.. Vertex(VRTX $48.04) down 2.69% coinciding with comments from the FDA that the Merck […]

Continue Reading 0

Biotech Movers du jour: Biogen (BIIB), Cubist(CBST), Nektar (NKTR)

Biogen(BIIB $103) soared 19% today reporting  profit of $294.3M EPS of $1.20 compared to $217.4 and EPS of 0.80 in the previous year. Revenue from its  drug Tysabri used to treat Crohn’s and MS grew 15% to $251M. The Company also reported late stage clinical data on its experimental oral MS drug BG-12. Biogen said […]

Continue Reading 0

Tech Leads Biotech Sector Higher, But Amgen (AMGN) and Gilead (GILD) Weak After Earnings

Tech Goes from Laggard to Leader Taking Strong  Biotech Sector Along for the Ride Tech stocks rallied big today with the NASDAQ up 2.1% to 2802, The Dow hit a new 2 1/2 year high up 1.5% to 12,453.The main catalyst was Intel (INTC $21.41) up 7.4% beating EPS estimates of 59 cents vs estimates […]

Continue Reading 0

Lackluster Trading In Biotech:Sell-Off Continues In Smaller Caps

Markets stabilized today with major indices up in the 0.4% range. Despite some weakness in meteoric biopharma stocks the healthcare sector is catching bids. Unloved and unwanted Johnson and Johnson(JNJ $61.87) is trying to shake off  product quality issues up 2.33%, raising its 2011 guidance with EPS in the $4.90-$5.00 range.A $20B deal  for Swiss […]

Continue Reading 0

Biotech Rally Ends With S&P Negative Outlook;But Amarin (AMRN) Soars

Even the biotech bulls bailed today on the double whammy of concern about Europe’s debt crisis and the S&P echoing the Tea Party refrain about the U.S. budget deficit and need for fiscal reform. As of mid-day trading both the S&P 500 and the NASDAQ is down are down 1.5% . Biotechnology stocks, up over 10% […]

Continue Reading 0

Biotech Stocks Roll Merrily Along Up 1%+

Drug and Biotechnology Stocks Up Across the Spectrum Its “groundhog day” in biotech world. Apparently money that has come out of tech stocks and money markets is going into healthcare stocks. In case you missed it even large cap drug stocks which have lagged the S&P YTD are in a rally mode. Are biotech stocks […]

Continue Reading 0